20 results about "Artery diseases" patented technology

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

A siRNA for inhibiting LPA gene expression, and a modifier and the use thereof, belonging to the field of biomedicine. Provided are a double-stranded RNA molecule targeting an LPA gene, and a modifier thereof. Both in vivo and in vitro experiments show that the provided double-stranded RNA molecule can effectively inhibit LPA gene expression, and can be used for preventing and / or treating Lp(a)-related diseases, such as thrombosis, atherosclerotic thrombosis, coronary artery disease, ischemic strokes, aortic valve stenosis, heart failure, atrial fibrillation, and peripheral artery disease.

Various embodiments described herein relate to systems, devices, and methods for non-invasive image-based plaque analysis and risk determination. In particular, in some embodiments, the systems, devices, and methods described herein are related to analysis of one or more regions of plaque, such as for example coronary plaque, using non-invasively obtained images that can be analyzed using computer vision or machine learning to identify, diagnose, characterize, treat and / or track coronary artery disease.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

Belongs to the technical field of medicine and health, and provides application of a novel compound containing a diaza subunit sulfonyl structure as a PKM2 agonist. The compound can be used for treating diseases related to PKM2 mediated regulation, including but not limited to tumors, immune diseases, hair loss, metabolic diseases, proliferation-dependent diseases, coronary artery diseases, Bloom syndromes, pulmonary arterial hypertension and the like. The specific diseases also relate to liver cancer, lung cancer, colorectal cancer, glioblastoma, breast cancer, kidney cancer, inflammatory bowel disease, ulcerative colitis, alopecia, lusterless disease, less hair and the like.

The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzo[d]azepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).

The present invention relates to 4-oxoretinoate for use in treatment or prevention of cardiac dysfunction, heart failure, or adverse cardiac remodelling after myocardial infarction or impaired cardiac blood flow. The present invention also relates to 4-oxoretinoate for use in treatment of coronary artery disease, or of ischemia-reperfusion injury.

Electrocardiogram technology is a method for monitoring the health state of the heart by measuring and recording the electrical activity of the heart. The technology is generally used for diagnosing various heart diseases, such as arrhythmia, coronary artery diseases, myocardial infarction and the like. Traditional electrocardiogram equipment is usually configured in hospitals and heart diagnosis and treatment centers and is operated by professional medical personnel. Along with the development of the technology, especially the progress of the sensor technology and the data processing technology, the electrocardiogram equipment has gradually developed towards the miniaturization and portability direction so as to meet the requirements of daily family use. Such devices allow ordinary users to perform self-monitoring of cardiac health without professional medical personnel present. However, in order to achieve monitoring accuracy and user experience similar to those of medical-grade equipment in household equipment, technical challenges in multiple aspects still face. The technical solution provided by the invention aims to overcome the limitation of the existing household electrocardiograph, provides a more advanced heart health monitoring tool, and the tool is high in accuracy, simple and convenient to operate and high in user friendliness, so that a non-professional user can easily use the tool, thereby better serving the vast family users, and improving the user experience. And the heart health management level is improved.

This disclosure provides crystalline forms of a compound of Formula (I), as well as pharmaceutically acceptable compositions thereof, and methods for their preparation and use in methods of treating hypercholesterolemia and other conditions related to PCSK9 activity, e.g., atherosclerosis, atherosclerotic cardiovascular disease, peripheral arterial disease, cerebrovascular disease, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Various embodiments described herein relate to systems, devices, and methods for non-invasive image-based plaque analysis and risk determination. In particular, in some embodiments, the systems, devices, and methods described herein are related to analysis of one or more regions of plaque, such as for example coronary plaque, using non-invasively obtained images that can be analyzed using computer vision or machine learning to identify, diagnose, characterize, treat and / or track coronary artery disease.

This disclosure generally relates to substituted quinolinone amide compounds or salts of formula (I), (II-A), (IV), or (III), and pharmaceutically active compositions thereof. The substituted quinolinone amide compounds or salts of formula (I), (II-A), (IV), or (III) disclosed herein may be used to treat or prevent heart disease in individuals where such treatment is necessary. Diseases treated by the methods described herein include, but are not limited to, heart disease. Cardiac diseases treated by the methods described herein include, but are not limited to, myocardial disease (cardiomyopathy), hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism. TIFF2026514388000407.tif65134

The present disclosure relates to methods and pharmaceutical compositions of angiotensin converting enzyme inhibitor and calcium channel blocker, particularly stable oral liquid compositions including angiotensin converting enzyme inhibitor, calcium channel blocker and one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

The application provides a coronary artery disease early prediction model construction method, system, device and medium. The application synchronously collects clinical covariates and fasting plasma lipidomics data of a subject, relies on a quality control system to ensure that the detection data is accurate and reliable, pre-processes and standardizes lipid characteristics, constructs unified model input variables in combination with clinical indicators, divides training sets and validation sets, screens core lipid characteristics in combination with CAD pathological mechanisms, eliminates redundant variables, and strengthens the relevance of characteristics and coronary artery lesions. A multivariate logistic regression model is constructed using the training set, and the validation set is used for evaluation to ensure the model discrimination performance and generalization ability. The key parameters of the model are solidified and a parameter table is formed, and a standardized CAD risk estimation model is established. In clinical application, only a single blood test combined with basic demographic information can quickly quantify the early disease risk, realize efficient screening and accurate risk stratification, and provide an objective basis for early warning and individualized clinical diagnosis and treatment of coronary artery disease.

The present disclosure relates to methods and pharmaceutical compositions of angiotensin converting enzyme inhibitor and calcium channel blocker, particularly stable oral liquid compositions including angiotensin converting enzyme inhibitor, calcium channel blocker and one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.